BioCentury | May 23, 2019
Tools & Techniques

As polygenic risk scores mature, opportunities emerge for disease interception

...from marketed products,” rather than investigational drugs, he said. Joseph Pickrell, CEO of test developer Gencove Inc....
...Society of Clinical Oncology (ASCO), Alexandria, Va. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Color, Burlingame, Calif. Gencove Inc....
...Low-density lipoprotein receptor PCSK9 - Proprotein convertase subtilisin/kexin type 9 Karen Tkach Tuzman, Associate Editor Celgene Corp. Color Gencove Inc. Johns...
BioCentury | May 3, 2019
Clinical News

Gencove gets SIBR grant to validate polygenic risk scores

...disease risk, with a first application in coronary heart disease. The grant was awarded to Gencove Inc....
...as better measures of disease risk than individual mutations (see "Bundled Inheritance" ). Mary Romeo, Staff Writer Gencove Inc. National...
Items per page:
1 - 2 of 2
BioCentury | May 23, 2019
Tools & Techniques

As polygenic risk scores mature, opportunities emerge for disease interception

...from marketed products,” rather than investigational drugs, he said. Joseph Pickrell, CEO of test developer Gencove Inc....
...Society of Clinical Oncology (ASCO), Alexandria, Va. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Color, Burlingame, Calif. Gencove Inc....
...Low-density lipoprotein receptor PCSK9 - Proprotein convertase subtilisin/kexin type 9 Karen Tkach Tuzman, Associate Editor Celgene Corp. Color Gencove Inc. Johns...
BioCentury | May 3, 2019
Clinical News

Gencove gets SIBR grant to validate polygenic risk scores

...disease risk, with a first application in coronary heart disease. The grant was awarded to Gencove Inc....
...as better measures of disease risk than individual mutations (see "Bundled Inheritance" ). Mary Romeo, Staff Writer Gencove Inc. National...
Items per page:
1 - 2 of 2